Structure via PubChem · Public domain (PubChem)
latrepirdine
Sign in to saveLatrepirdine (INN, also known as dimebolin and sold as Dimebon) is an antihistamine drug which has been used clinically in Russia since 1983.
In the Vinony graph
Within Vinony's link graph, latrepirdine is referenced by 1,859 other articles, and connects out to propranolol, adrenergic receptor and N-methylserotonin.
Vinony files it under Chemical pages without DrugBank identifier, Drugs in the Soviet Union and Drugs not assigned an ATC code.
Its subject is documented across 7 Wikipedia language editions.
Chemical data
- Formula
- C21H25N3
- Molecular weight
- 319.4 g/mol
- IUPAC name
- 2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole
- SMILES
- CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C
- InChIKey
- JNODQFNWMXFMEV-UHFFFAOYSA-N
- XLogP
- 3.5
- Polar surface area
- 21.1 Ų
- H-bond donors
- 0
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- Alzheimer disease, Huntington disease, liver failure
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Has part
- carbon
- Mass
- 319.205
Show 4 more facts
- chemical formula
- C₂₁H₂₅N₃
- canonical SMILES
- CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C
- Commons category
- Latrepirdine
- subject has role
- nootropic
Sources (2)
via Wikidata · CC0
~4 min read
Encyclopedic overview
7 sectionsContents
- Uses
- Clinical trials
- Alzheimer's disease
- Huntington's disease
- Pharmacology
- See also
- References
Latrepirdine (INN, also known as dimebolin and sold as Dimebon) is an antihistamine drug which has been used clinically in Russia since 1983.
Research was conducted in both Russia and western nations into potential applications as a neuroprotective drug to treat Alzheimer's disease and, possibly, as a nootropic, as well. After a major phase III clinical trial for Alzheimer's disease (AD) treatment failed to show any benefit, three other AD trials continued. Major industry-based development in this indication essentially stopped after another Phase III trial suffered the same fate in 2012. Latrepirdine failed in the phase III trial for Huntington's disease.
Excerpted from Wikipedia’s “latrepirdine” article, available under the CC BY-SA 4.0 licence.